Abeona Therapeutics (ABEO) Common Equity (2011 - 2026)

Abeona Therapeutics' Common Equity history runs 16 years deep, the most recent figure standing at $144.9 million for Q1 2026.

• In Q1 2026, Common Equity rose 250.13% year-over-year to $144.9 million; the TTM figure through Mar 2026 stood at $144.9 million (up 250.13% YoY), while the FY2025 annual figure was $159.2 million, up 261.6% from the prior year.
• Common Equity was $144.9 million for Q1 2026 at Abeona Therapeutics, down from $159.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $171.2 million in Q3 2025 to a low of -$8.9 million in Q1 2024.
• Historically, Common Equity has averaged $57.3 million across 5 years, with a median of $26.8 million in 2022.
• Biggest YoY gain for Common Equity was 683.75% in 2024; the steepest drop was 147.39% in 2024.
• A 5-year view of Common Equity shows it stood at $26.8 million in 2022, then tumbled by 44.6% to $14.8 million in 2023, then jumped by 196.99% to $44.0 million in 2024, then soared by 261.6% to $159.2 million in 2025, then declined by 8.97% to $144.9 million in 2026.
• The last three Common Equity figures came in at $144.9 million (Q1 2026), $159.2 million (Q4 2025), and $171.2 million (Q3 2025), per Business Quant data.